EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies

Jue Zhang, Sarah Webster, Bret Duffin, Matthew N Bernstein, John Steill, Scott Swanson, Matthew H Forsberg, Jennifer Bolin, Matthew E Brown, Aditi Majumder, Christian M Capitini, Ron Stewart und 2 weitere

Stem Cell Reports · 2023-02 · 18 (2) · 585-596

DOI: 10.1016/j.stemcr.2022.12.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cell Reports, 2023-02. Verfasst von Jue Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Morgridge Institute for Research, Madison, WI 53715, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Pluripotent Stem Cells, Melanoma, Neuroblastoma. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophages armed with chimeric antigen receptors (CARs) provide a potent new option for treating solid tumors. However, genetic engineering and scalable production of somatic macrophages remains significant challenges. Here, we used CRISPR-Cas9 gene editing methods to integrate an anti-GD2 CAR into the AAVS1 locus of human pluripotent stem cells (hPSCs). We then established a serum- and feeder-free differentiation protocol for generating CAR macrophages (CAR-Ms) through arterial endothelial-to-hematopoietic transition (EHT). CAR-M produced by this method displayed a potent cytotoxic activity against GD2-expressing neuroblastoma and melanoma in vitro and neuroblastoma in vivo. This study provides a new platform for the efficient generation of off-the-shelf CAR-Ms for antitumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenPluripotent Stem CellsMelanomaNeuroblastomaHumansReceptors, Antigen, T-CellImmunotherapyMacrophages

Stichwörter der Autor:innen

CARGD2PSCschimeric antigen receptorhemogenic endotheliumimmunotherapymacrophagesmelanomaneuroblastomapluripotent stem cells

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Morgridge Institute for Research, Madison, WI 53715, USA.
  • Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53792, USA.
  • Department of Surgery, University of Wisconsin-Madison, Madison, WI 53792, USA.
  • Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53792, USA; Carbone Cancer Center, University of Wisconsin-Madison, Madison 53705, WI, USA.
  • Morgridge Institute for Research, Madison, WI 53715, USA. Electronic address: jthomson@morgridge.org.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NHLBI NIH HHS
  • NIH
  • National Heart, Lung, and Blood Institute
  • Novartis
  • Baylor College of Medicine

Zitieren

APA

Zhang, J., Webster, S., Duffin, B., Bernstein, M. N., Steill, J., Swanson, S., Forsberg, M. H., Bolin, J., Brown, M. E., Majumder, A., Capitini, C. M., Stewart, R., Thomson, J. A., & Slukvin, I. I. (2023). Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports, 18(2), 585-596. https://doi.org/10.1016/j.stemcr.2022.12.012

Vancouver

Zhang J, Webster S, Duffin B, Bernstein MN, Steill J, Swanson S, et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports. 2023;18(2):585-596. doi:10.1016/j.stemcr.2022.12.012

BibTeX
@article{Zhang2023,
  author = {Zhang, Jue and Webster, Sarah and Duffin, Bret and Bernstein, Matthew N and Steill, John and Swanson, Scott and Forsberg, Matthew H and Bolin, Jennifer and Brown, Matthew E and Majumder, Aditi and Capitini, Christian M and Stewart, Ron and Thomson, James A and Slukvin, Igor I},
  title = {Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies},
  journal = {Stem Cell Reports},
  year = {2023},
  volume = {18},
  number = {2},
  pages = {585--596},
  doi = {10.1016/j.stemcr.2022.12.012}
}
Kostenlos starten →